Topical application of novel anti-microbial peptide, AG30/5C, for cutaneous ulcers

Topical application of novel anti-microbial peptide, AG30/5C, for cutaneous ulcers - Topical application of AG30/5C for cutaneous ulcers

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010268

Enrollment

Registered

2013-03-18

Start date

2013-03-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous ulcers

Interventions

topical treatment of AG30/5C (100microg/mL)twice a day for 11 days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. patients with diabetes, peripheral arterial diseases, and Buerger diseases. 2. uncured cutaneous ulcer for more than one month 3. detection of MRSA in ulcer 4. no infection of cutaneous ulcer 5. no infection of other cutaneous ulcer 6. no systematic infection 7. over 20 years old 8. agreement with patient

Exclusion criteria

Exclusion criteria: 1. Patients with complication of alcohol and drug intoxication 2. History of malignant tumor 3. Tumor multiplication in ulcer 4. Infection with HIV, HBV, HCV, HTLV-1 5. Pregnancy 6. Osteomyelitis of ulcer 7. Unsuitable patients judged by investigators

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Wound size Anti-bacterial action	—

Countries

Japan

Contacts

Public ContactHironori Nakagami

Osaka University Division of Vascular Medicine and Epigenetics

nakagami@gts.med.osaka-u.ac.jp06-6879-3406

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026